Sunil Babu
3 Papers
Sunil Babu is an academic researcher. The author has contributed to research in topics: Lung cancer & Nivolumab. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)
David R. Spigel,Craig W. Reynolds,David M. Waterhouse,Edward B. Garon,Jason C. Chandler,Sunil Babu,Paul Thurmes,Alexander I. Spira,Robert M. Jotte,Jin Zhu,Wen Hong Lin,George R. Blumenschein +11 more
TL;DR: Findings do not support further evaluation of nivolumab 240 mg every 2 weeks plus crizotinib 250 mg twice daily in patients with previously untreated advanced ALK translocation–positive NSCLC.
206
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153).
David R. Spigel,Michael McCleod,Robert M. Jotte,Lawrence H. Einhorn,Leora Horn,David M. Waterhouse,Ben C. Creelan,Sunil Babu,Natasha B. Leighl,Jason C. Chandler,Félix Couture,George Keogh,Glenwood D. Goss,Davey B. Daniel,Edward B. Garon,Lee S. Schwartzberg,Rohini Sen,Beata Korytowsky,Ang Li,Nivedita Aanur,Maen A. Hussein +20 more
TL;DR: Data from this large predominantly community-based study are consistent with registrational studies, and the median OS for patients with an ECOG PS of 2 was lower than for the overall population, but comparable with historical data.
178
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
David M. Waterhouse,Edward B. Garon,Jason C. Chandler,Michael McCleod,Maen A. Hussein,Robert M. Jotte,Leora Horn,Davey B. Daniel,George P. Keogh,Ben C. Creelan,Lawrence H. Einhorn,Justin N. Baker,Samer Kasbari,Petros Nikolinakos,Sunil Babu,Félix Couture,Natasha B. Leighl,Craig Reynolds,George R. Blumenschein,Vijay Gunuganti,Ang Li,Nivedita Aanur,David R. Spigel +22 more
TL;DR: Findings from an exploratory analysis of CheckMate 153 represent the first randomized data on continuous versus fixed-duration immunotherapy in previously treated advanced NSCLC and suggest that continuing nivolumab beyond 1 year improves outcomes.
161